Outcome Prediction of Hematologic Malignancy in Critically Sick People

Biomed Res Int. 2022 Jul 18:2022:3234484. doi: 10.1155/2022/3234484. eCollection 2022.

Abstract

People with hematologic malignancies (HM) frequently postulate intensive care unit (ICU) hospitalization due to organ damage caused by the disease process or treatment-related consequences. This study is aimed at looking at mortality and sign factors in adult patients with hematologic malignancy (HM) who have been hospitalized in the ICU. Death was one quality indicator; researchers used a machine learning approach to find determinants of death. As per the study, there have been 206 patients hospitalized in the ICU (mean age: 51.3 ± 13.6 years; 60% male). The average length of stay was three days, with 14.1% requiring extended ICU commitment. ICU death was 45.6% at 30 days, 62.6% at sixty days, and 74.3% at twelve months, rising to 59.2% at thirty days, 62.6% at sixty days, and 74.3% at twelve months. Ventilation systems and vasodilating medication were linked to higher ICU death, but admission to the ICU surgically and experiencing malignancies are linked with lower death rates. Patients with HM who are hospitalized in the ICU have a high mortality rate (45.6%), which rises to 74.3% after a year. Serious illness, postsurgical hospitalization, and malignancy were revealed as determinants of patient outcomes in multivariate analyses.

Publication types

  • Retracted Publication

MeSH terms

  • Adult
  • Critical Illness
  • Female
  • Hematologic Neoplasms* / drug therapy
  • Hospital Mortality
  • Hospitalization
  • Humans
  • Intensive Care Units
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies